NASDAQ:ACOR Acorda Therapeutics - ACOR News Today Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Acorda Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.92 -0.03 (-3.16%) (As of 02/1/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.90▼$0.9650-Day Range$0.52▼$1.0052-Week Range$0.26▼$2.29Volume136,437 shsAverage Volume305,645 shsMarket Capitalization$22.34 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Get Acorda Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACOR and its competitors with MarketBeat's FREE daily newsletter. Email Address ACOR Media Mentions By Week ACOR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACOR News Sentiment▼0.630.69▲Average Medical News Sentiment ACOR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACOR Articles This Week▼21▲ACOR Articles Average Week All Sources Trusted Sources MarketBeat.com Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAcorda Therapeutics to Present at Sequire Biotechnology Conferencefinance.yahoo.com - January 31 at 8:25 PMStockNews.com Upgrades Acorda Therapeutics (NASDAQ:ACOR) to "Buy"americanbankingnews.com - January 30 at 4:50 AMShort Interest in Acorda Therapeutics, Inc. (NASDAQ:ACOR) Decreases By 8.1%americanbankingnews.com - January 24 at 7:59 AMMethyl Salicylate Patches Market Register to Growth by 2023-2027 | Global Revenue and Key Dynamics with Industry Segmentsmarketwatch.com - January 23 at 2:59 PMRepeat Expansion Disorders Treatment Market 2023 Expected to Witness the Highest Revenue Growth Over Forecast to 2029marketwatch.com - January 17 at 7:35 AMAcorda Therapeutics Announces New Agreement with Catalent for Long-Term Global Supply of INBRIJA®finance.yahoo.com - January 5 at 6:29 PMAcorda Therapeutics Announces Revised Long-Term Financial Guidancefinance.yahoo.com - December 22 at 11:04 AMAcorda Therapeutics gets Nasdaq delisting notice, plans to appeal decisionmsn.com - December 21 at 5:45 AMAcorda Therapeutics Receives Nasdaq Listing Determination Letter and Plans to Request a Hearingfinance.yahoo.com - December 20 at 8:22 PMSpinal Cord Trauma Treatment Market 2023 : Manufacturers Strategies, Share Estimation, Future Demand and Regional Growth Dynamics 2028marketwatch.com - December 9 at 11:05 AMAcorda Edges up on Making Interest Paymentbaystreet.ca - December 5 at 3:34 PMAcorda Therapeutics Makes December 2022 $6.2 Million Interest Payment on Secured Debt in Cashfinance.yahoo.com - December 5 at 9:02 AMAcorda Therapeutics Third Quarter 2022 Earnings: US$0.57 loss per share (vs US$2.43 loss in 3Q 2021)finance.yahoo.com - November 19 at 7:15 PMAcorda Therapeutics Announces Passage of Reverse Stock Split Proposal at its Special Meeting of Stockholdersfinance.yahoo.com - November 11 at 12:47 PMHow Is The Market Feeling About Acorda Therapeutics?msn.com - November 9 at 5:59 PMAcorda Therapeutics Reports Third Quarter 2022 Financial Resultsfinance.yahoo.com - November 1 at 9:51 PMAcorda Therapeutics supplies long-term guidance and business plan in preparation for shareholders meetingproactiveinvestors.com - November 1 at 9:57 AMAcorda Therapeutics shares fly after it provides fresh revenue guidanceproactiveinvestors.com - November 1 at 9:57 AMAcorda Therapeutics Provides Long-Term Business Plan and Financial Guidancefinance.yahoo.com - October 27 at 4:55 PMAcorda Third Quarter 2022 Update: Webcast/Conference Call Scheduled for November 1, 2022finance.yahoo.com - October 25 at 4:58 PMAcorda Shareholders Invited to Virtual Q&A with CEO Ron Cohen, M.D.finance.yahoo.com - October 21 at 7:22 AMWhy Ericsson Shares Are Trading Lower? Here Are 56 Stocks Moving In Thursday's Mid-Day Sessionmsn.com - October 20 at 4:06 PMISS, Glass Lewis, and Egan-Jones Recommend that Acorda Stockholders Vote FOR the Proposal to Implement a Reverse Stock Splitfinance.yahoo.com - October 19 at 7:05 AMAcorda Therapeutics Will Not Use Shares for December 2022 $6.2 Million Interest Payment on Secured Debtfinance.yahoo.com - October 18 at 10:05 AMAcorda Shares Surge Premarket on Ampyra Arbitration Win >ACORmarketwatch.com - October 17 at 8:30 AMAcorda Announces $16.5 Mln Award And Royalty/Supply Relief In AMPYRA Arbitration Case With Alkermesmarkets.businessinsider.com - October 16 at 10:25 PMAcorda Withdraws Proposal To Raise Authorized Shares From Special Meeting Of Stockholdersnasdaq.com - October 10 at 11:45 AMAcorda Therapeutics Withdraws Proposal to Increase Authorized Shares from Special Meeting of Stockholdersfinance.yahoo.com - October 10 at 6:44 AMDefence Therapeutics Inc.: Defence Therapeutics Applauds United States President Biden Cancer Moonshot Initiativefinanznachrichten.de - September 23 at 4:56 PMAcorda Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conferencefinance.yahoo.com - September 8 at 8:19 PMAcorda Enters License Agreement For Nepicastatnasdaq.com - August 29 at 9:14 AMAcorda Therapeutics Enters into License Agreement with Asieris Pharmaceuticalsfinance.yahoo.com - August 29 at 9:14 AMAcorda Therapeutics COO Lauren Sabella To Resignnasdaq.com - August 19 at 12:47 PMAcorda Therapeutics Announces Resignation of Chief Operating Officerfinance.yahoo.com - August 19 at 12:47 PMAcorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q2 2022 Results - Earnings Call Transcriptseekingalpha.com - August 7 at 3:41 PMAcorda Therapeutics Misses Q2 EPS by $2.79investing.com - August 7 at 12:10 AMAcorda Therapeutics Non-GAAP EPS of -$3.15, revenue of $31.05Mseekingalpha.com - August 7 at 12:10 AMAcorda Therapeutics Reports Second Quarter 2022 Financial Resultsfinance.yahoo.com - August 4 at 7:08 PMAcorda Therapeutics Inc Stock Quote ACORmorningstar.com - July 30 at 6:38 AMAcorda Second Quarter 2022 Update: Webcast/Conference Call Scheduled for August 4, 2022finance.yahoo.com - July 28 at 6:19 PMNano-cap biotech Acorda surges 50% on drug launch in Germanyseekingalpha.com - June 16 at 6:09 PMWhy Acorda Therapeutics Shares Gaining Today?finance.yahoo.com - June 16 at 1:08 PMEsteve Launches INBRIJA® in Germanyfinance.yahoo.com - June 16 at 8:07 AMAcorda Therapeutics, Inc. Provides Notice of Data Privacy Eventmarkets.businessinsider.com - June 14 at 9:02 PMAcorda Therapeutics Now the Least Expensive vs. Cardano This Yearnasdaq.com - May 18 at 6:55 PMAcorda Therapeutics, Inc. 2022 Q1 - Results - Earnings Call Presentationseekingalpha.com - May 14 at 6:52 PMAcorda partners with Biopas to sell Parkinson's disease therapy in Latin Americaseekingalpha.com - May 11 at 7:32 PMAcorda Therapeutics and Biopas Laboratories Announce Agreement to Commercialize INBRIJA® in Latin Americafinance.yahoo.com - May 11 at 7:32 PMAcorda Therapeutics Reports First Quarter 2022 Financial Resultsfinance.yahoo.com - May 11 at 7:32 PMAcorda First Quarter 2022 Update: Webcast/Conference Call Scheduled for May 11, 2022finance.yahoo.com - May 4 at 7:38 PM Get Acorda Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACOR and its competitors with MarketBeat's FREE daily newsletter. Email Address This page (NASDAQ:ACOR) was last updated on 2/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.